Perovic, Vladimir http://orcid.org/0000-0002-1994-1738
Sabol, Ivan http://orcid.org/0000-0002-5753-8528
Grce, Magdalena http://orcid.org/0000-0001-6178-8418
Inngjerdingen, Marit
Pulanic, Drazen
Peric, Zinaida http://orcid.org/0000-0001-9458-8025
Peczynski, Christophe http://orcid.org/0000-0002-3829-0088
Polge, Emmanuelle
Koenecke, Christian http://orcid.org/0000-0001-7025-1735
Dickinson, Anne
Greinix, Hildegard
Basak, Grzegorz
Penack, Olaf http://orcid.org/0000-0003-4876-802X
Scherwath, Angela
Barata, Anna http://orcid.org/0000-0003-0297-5920
Olivieri, Attilio
Lawitschka, Anita http://orcid.org/0000-0002-4843-4735
Mensah-Glanowska, Patrycja http://orcid.org/0000-0002-9850-2206
Andrikovics, Hajnalka
Schoemans, Helene http://orcid.org/0000-0002-7568-8239
Wolff, Daniel
Funding for this research was provided by:
European Cooperation in Science & Technology under the COST Action 17138
European Cooperation in Science and Technology (COST), COST Action 17138
European Cooperation in Science & Technology under the COST Action 17138
European Cooperation in Science & Technology under the COST Action 17138
European Cooperation in Science & Technology under the COST Action 17138
European Cooperation in Science & Technology under the COST Action 17138
European Cooperation in Science & Technology under the COST Action 17138
European Cooperation in Science & Technology under the COST Action 17138
European Cooperation in Science & Technology under the COST Action 17138
European Cooperation in Science & Technology under the COST Action 17138
European Cooperation in Science & Technology under the COST Action 17138
European Cooperation in Science & Technology under the COST Action 17138
European Cooperation in Science & Technology under the COST Action 17138
Article History
Received: 1 August 2021
Revised: 26 May 2022
Accepted: 30 May 2022
First Online: 11 June 2022
Competing interests
: DW received honoraria from Novartis, Mallinckrodt, MACO, Janssen, Behring and Incyte. Between 2017 and 2021, H.S. has participated in the Advisory Boards for Incyte, Janssen & Novartis; received speaker’s fees from Novartis, Incyte, Jazz Pharmaceuticals, Takeda and the BHS (Belgian Haematological Society); received travel grants from the EBMT, the CIBMTR, Celgene, Abbvie, Incyte & Gilead and research funding from Novartis and the BHS. All other authors declare no conflict of interest. OP has received honoraria or travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, Novartis, Pfizer and Therakos. He has received research support from Gilead, Incyte, Jazz, Neovii Biotech and Takeda. He is a member of advisory boards to Jazz, Gilead, MSD, Omeros, Priothera, Shionogi and SOBI. Other authors declare no competing interests.